Technical Reports on Drug Makers Stocks -- Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and Immune Pharma
NEW YORK, March 17, 2017 /PRNewswire/ --
For today, Stock-Callers.com directs investors' attention to four major stocks in the Drug Manufacturers space: Bristol-Myers Squibb Co. (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Co. (NYSE: LLY), and Immune Pharmaceuticals Inc. (NASDAQ: IMNP). These companies operate in the Healthcare sector, which was mostly underwater in afternoon trade on Thursday, March 16th, 2017, with the NYSE Health Care Index dropping almost 0.6%, while shares of health care companies in the S&P 500 were down 1.0% as a group. Download the free research reports on these stocks today:
http://stock-callers.com/registration
Bristol-Myers Squibb
New York headquartered Bristol-Myers Squibb Co.'s shares fell 0.59%, closing Thursday's trading session at $57.31. The stock recorded a trading volume of 9.90 million shares. The Company's shares have advanced 6.70% in the last month and 0.91% over the previous three months. The stock is trading 5.02% above its 50-day moving average. Additionally, shares of Bristol-Myers Squibb, which discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide, have a Relative Strength Index (RSI) of 55.55.
On March 02nd, 2017, Bristol-Myers' Board of Directors of declared a quarterly dividend of $0.39 per share on the $.10 par value Common Stock of the corporation, payable on May 01st, 2017, to stockholders of record at the close of business on April 07th, 2017. The directors also declared a quarterly dividend of $0.50 per share on the $2.00 Convertible Preferred Stock of the Corporation, payable June 01st, 2017 to stockholders of record at the close of business on May 09th, 2017. See our free and comprehensive research report on BMY at:
http://stock-callers.com/registration/?symbol=BMY
AstraZeneca
On Thursday, shares in Cambridge, the UK headquartered AstraZeneca PLC recorded a trading volume of 3.10 million shares. The stock rose 1.03%, ending the day at $30.52. The Company's shares have advanced 6.56% in the past month, 13.84% in the last three months, and 15.42% over the previous one year. The stock is trading above its 50-day and 200-day moving averages by 8.62% and 5.56%, respectively. Furthermore, shares of AstraZeneca, which engages in the discovery, development, and commercialization of prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, autoimmune, infection, gastrointestinal, and neuroscience diseases worldwide, have an RSI of 71.28.
On March 14th, 2017, AstraZeneca presented results from the Phase-III SOLO-2 trial demonstrating a significant improvement in progression-free survival (PFS) in germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer patients treated with LYNPARZA™ tablets, compared with placebo in the maintenance setting. The trial met its primary endpoint of investigator-assessed PFS. PFS as measured by Blinded Independent Central Review evaluation, a pre-specified sensitivity analysis supporting the primary endpoint, demonstrated a median PFS of 30.2 months versus 5.5 months for placebo. AZN free research report PDF is just a click away at:
http://stock-callers.com/registration/?symbol=AZN
Eli Lilly
Indianapolis, Indiana headquartered Eli Lilly and Co.'s stock finished the day 1.04% lower at $84.99. A total volume of 4.74 million shares was traded, which was above their three months average volume of 4.35 million shares. The Company's shares have advanced 7.84% in the last one month, 24.65% in the previous three months, and 16.33% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 7.87% and 11.02%, respectively. Additionally, shares of Eli Lilly, which discovers, develops, manufactures, and markets pharmaceutical products worldwide, have an RSI of 66.44.
On March 04th, 2017, Eli Lilly announced that patients with moderate-to-severe plaque psoriasis treated with Taltz® (ixekizumab) demonstrated superior efficacy at 24 weeks compared to patients treated with Stelara®* (ustekinumab). The Company noted that at 24 weeks, patients treated with Taltz achieved significantly higher response rates compared to patients treated with Stelara, including 83% of patients who achieved Psoriasis Area Severity Index (PASI) 90 - the study's primary endpoint - compared to 59% of patients who achieved PASI 90 after treatment with Stelara. Sign up for your complimentary report on LLY at:
http://stock-callers.com/registration/?symbol=LLY
Immune Pharma
Shares in New York headquartered Immune Pharmaceuticals Inc. ended yesterday's session 0.67% higher at $0.16 with a total trading volume of 1.55 million shares. The stock is trading 12.08% below its 50-day moving average. Shares of the Company, which develops and commercializes novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas, have an RSI of 38.17.
On March 13th, 2017, Immune Pharma announced that the NASDAQ Hearings Panel granted the Company's request for additional time to comply with NASDAQ listing requirements, subject to the following: (i) on or before April 14th, 2017, the Company must inform the Panel that it has effected a split in a ratio sufficient to cure the deficiency and (ii) on or before May 01st, 2017, the Company must have evidenced a closing bid price of $1.00 or more for a minimum of ten prior consecutive trading days. Register for free on Stock-Callers.com and download the latest research report on IMNP at:
http://stock-callers.com/registration/?symbol=IMNP
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Share this article